Vividion Therapeutics, a subsidiary of Bayer AG, has commenced a Phase I clinical trial for VVD-130850, an oral STAT3 inhibitor intended to treat advanced solid and hematologic tumors.

Thermosome has received approval from the Data Safety Monitoring Board (DSMB) to continue with the planned dosage increase in its Phase I clinical trial for THE001.

MiNK Therapeutics's primary product, AGENT-797, is currently undergoing multiple Phase 1 clinical trials, with anticipated results to be released later this year.

Prokarium has initiated a Phase I/Ib clinical trial, known as PARADIGM-1, for non-muscle invasive bladder cancer (NMIBC) patients.

REGENXBIO has successfully completed patient recruitment for the second group in the Phase I/II AFFINITY DUCHENNE® clinical trial, which is examining the safety and effectiveness of RGX-202.

REGENXBIO Inc. (Nasdaq: RGNX) revealed that the Phase I/II/III CAMPSIITE® clinical trial for RGX-121, a treatment for Mucopolysaccharidosis Type II (MPS II).

Genenta Science, a clinical-stage biotech firm specializing in immuno-oncology, has made significant progress in its Phase 1/2 clinical trial for Temferon™.

Belhaven Biopharma announced promising results from its Phase 1 clinical trial of Nasdepi, a nasal dry powder epinephrine device for treating anaphylaxis due to severe allergic reactions.

Hemogenyx Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) to commence Phase I clinical trials for its innovative HEMO-CAR-T treatment for acute myeloid leukemia (AML).

HMB-001, a novel bispecific antibody developed by Hemab Therapeutics, has shown promising results in Phase 1 clinical trials for treating Glanzmann Thrombasthenia.

Anixa Biosciences has initiated treatment for a fourth participant in its Phase 1 clinical trial for a new CAR-T cell therapy aimed at ovarian cancer.

Nuvalent has commenced the Phase 2 stage of the ALKOVE-1 clinical trial for NVL-655, a novel ALK-selective tyrosine kinase inhibitor (TKI).